Bimosiamose
Bimosiamose 性质
| 熔点 | 115-117° |
|---|---|
| 沸点 | 1051.0±65.0 °C(Predicted) |
| 密度 | 1.417±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO:100.0(最大浓度 mg/mL);115.89(最大浓度 mM) 0.1 M NaOH:25.0(最大浓度 mg/mL);28.97(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 3.95±0.10(Predicted) |
| 颜色 | 白色至米白色 |
Bimosiamose 用途与合成方法
IC50: 88 μM (E-selectin), 20 μM (P-selectin), 86 μM (L-selectin)
Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils.
Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved.
| Animal Model: | Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R) |
| Dosage: | 25 mg/kg |
| Administration: | Intravenous injection |
| Result: | Showed a significant increase in survival compared with controls. |
Bimosiamose 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-106139 | Bimosiamose | 187269-40-5 | 1mg | 600 |
| 2025-12-22 | HY-106139 | Bimosiamose | 187269-40-5 | 5mg | 1800 |
